Drugs / SM3321
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06087770 | Dec 2023 → Aug 2025 | — | Beijing StarMab Biomed Technology Ltd | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SM3321 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06087770 ↗ |
| Route | Intravenous | “Intravenous infusion, once a week, 28 days for a dosing cycle” NCT06087770 ↗ |